KEYNOTE-522 Demonstrates Potential for Immunotherapy in Triple-Negative Breast Cancer

KEYNOTE-522: 5-year follow-up of pembrolizumab in triple-negative breast cancerПодробнее

Immunotherapy Keytruda Shows Benefit in Early Triple-Negative Breast CancerПодробнее

KEYNOTE-522: Immune therapy and chemotherapy in patients with early triple negative breast cancerПодробнее

Phase 3 KEYNOTE-522 results: pembro/chemo neoadjuvant, pembro adjuvant in early TNBCПодробнее

KEYNOTE-522: Neoadjuvant and adjuvant pembrolizumab for early TNBCПодробнее

New directions in immunotherapy for improving outcomes in TNBCПодробнее

KEYNOTE 522: pembrolizumab as neoadjuvant treatment for early TNBCПодробнее

KEYNOTE-522 updates: Pembrolizumab plus neoadjuvant chemotherapy in early triple-negative breast...Подробнее

Breast Cancer ESMO 2024 Highlights: Key Studies Discussed NATALEE, KEYNOTE 522, DESTINY-Breast12Подробнее

Exploratory analysis of KEYNOTE-522: EFS after neoadjuvant pembro + chemo Vs chemo for early TNBCПодробнее

Triple Negative Breast Cancer Update: Immunotherapy in stage 2-3 TNBC (KEYNOTE 522 Update)Подробнее

Encouraging developments in triple negative breast cancer immunotherapyПодробнее

Dr. Rugo on the Results of the KEYNOTE-522 Trial in TNBCПодробнее

KEYNOTE-522: final OS findings of pembrolizumab and chemotherapy in TNBCПодробнее

Neoadjuvant Durvalumab Shows Benefit in Triple-Negative Breast CancerПодробнее

Longer Overall Survival in Metastatic TNBC With Pembrolizumab - Medpage TodayПодробнее

Latest on Immunotherapy in Triple-Negative Breast Cancer - Medpage TodayПодробнее

Update on Keynote 522, the current standard of care for triple negative breast cancer.Подробнее

How immunotherapy might be effective for triple-negative breast cancerПодробнее